In recent years, health policy pushes have seen an increasing focus on drug costs. Proposals have embraced concepts like price referencing, transparency requirements, and drug importation. In this report, I examine congressional legislation and commercial payer positions on these approaches. The data reveal little opposition to policies such as international reference pricing or drug importation.
Â
Neumann U. (2020). The Escalating US Policy Environment. Payer Views on Current Drug Pricing Proposals. Certara.
Commenti